Study Supports Adjuvant Chemo for Resected Stage 3 Small Bowel Cancer
Adjuvant chemotherapy may be effective for patients with resected stage 3 small bowel adenocarcinoma and select patients with earlier stage disease.
Diagnosis & Disease Information
Being overweight during teenage years may increase risk of bowel cancer
Obesity during one’s teenage years could greatly increase that chances of developing bowel cancer by middle age.
Most patients with bowel cancer not advised to exercise despite its health benefits
Many patients with bowel cancer say they were not advised to exercise regularly after diagnosis.
Bowel cancer screening less likely with low numeracy skills
Those who have trouble understanding numbers may be less likely to undergo screening for bowel cancer.
For patients with bowel cancer, screening may extend survival despite late stage diagnosis
Patients with late stage bowel cancer who are diagnosed through screening may have a better prognosis.
High fat diet linked to increased risk of bowel cancers
A team of researchers has found that gut bacteria associated with high fat diets cause an increased risk of bowel cancer.
Daily dose of aspirin significant lowers cancer risk
In a recent study, researchers found that by taking a daily aspirin, the incidence of gastrointestinal cancers is reduced, as well as a reduction in cancer-specific mortality.
Existing medicines promising for stomach and bowel cancer
Stomach and bowel cancer—two of the most common cancers worldwide—could be treated with a class of medicines that are currently used to treat a blood disorder, according to new research.
Comorbidities markedly decrease cancer survival
Cancer survival tends to be far lower when patients have comorbid diseases, based on a systematic review of 10 years of data from Denmark and elsewhere. The effects of comorbidities on survival varied by cancer type, but overall trends were comparable, researchers said.
Regorafenib prolongs survival in face of GI cancers
Persons with metastatic colorectal cancer or gastrointestinal stromal tumors may garner some survival benefit from regorafenib after standard treatments have failed.
- Loading...
Loading...
Loading... 
Loading...